medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2004, Number 3

<< Back Next >>

Ann Hepatol 2004; 3 (3)

Nonalcoholic fatty liver disease

Grant LM, Lisker-Melman M

Language: English
References: 66
Page: 93-99
PDF size: 113.57 Kb.


Text Extraction

Nonalcoholic fatty liver disease is a clinicopathologic syndrome that encompasses several clinical entities. The spectrum of conditions ranges from simple steatosis to steatohepatitis, fibrosis and end stage liver disease. The condition was originally described in obese, diabetic, middle-aged females without a history of significant alcohol use with liver histology consistent with alcoholic hepatitis. It is known that this entity occurs without any particular sex predilection, in lean individuals, as well as an increasing number of obese children.
Other terms have been used to describe this clinical entity such as alcohol-like hepatitis, pseudo-alcoholic hepatitis, diabetic hepatitis and steatonecrosis. Ludwig and colleagues introduced the term nonalcoholic steatohepatitis (NASH) to describe patients fitting the picture of alcoholic hepatitis but without a history of significant alcohol abuse. The term nonalcoholic fatty liver disease (NAFLD) is used more frequently to include the spectrum of conditions that range from steatosis through steatohepatitis, fibrosis and cirrhosis. NASH is reserved for patients with steatohepatitis and fibrosis.
NAFLD is now being recognized as the most common cause of elevated liver enzymes in the United States. Although the exact etiology of NAFLD is not known, it may be caused by insulin resistance coupled with increased oxidative stress to the hepatocytes. No specific therapy has been approved for this condition and the mainstay of management is weight loss.


REFERENCES

  1. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989; 20(6): 594-8.

  2. Ludwig J, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55(7): 434-8.

  3. Bacon BR, et al. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107(4): 1103-9.

  4. Sathya P, Martin S, Alvarez F. Nonalcoholic fatty liver disease (NAFLD) in children. Curr Opin Pediatr 2002; 14(5): 593-600.

  5. Marchesini G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50(8): 1844-50.

  6. Kumar KS, Malet PF. Nonalcoholic steatohepatitis. Mayo Clin Proc 2000; 75(7): 733-9.

  7. Falck-Ytter Y, et al. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001; 21(1): 17-26.

  8. Marcos A, et al. Selection and outcome of living donors for adult to adult right lobe transplantation. Transplantation 2000; 69(11): 2410-5.

  9. Hilden M, et al. Liver histology in a ‘normal’ population-examinations of 503 consecutive fatal traffic casualties. Scand J Gastroenterol 1977; 12(5): 593-7.

  10. Ground KE. Liver pathology in aircrew. Aviat Space Environ Med 1982; 53(1): 14-8.

  11. Kopelman PG. Obesity as a medical problem. Nature 2000; 404(6778): 635-43.

  12. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med 2002; 346(8): 591-602.

  13. Mokdad AH, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289(1): 76-9.

  14. Ford ES, Williamson DF, Liu S. Weight change and diabetes incidence: findings from a national cohort of US adults. Am J Epidemiol 1997; 146(3): 214-22.

  15. Resnick HE, et al. Relation of weight gain and weight loss on subsequent diabetes risk in overweight adults. J Epidemiol Community Health 2000; 54(8): 596-602.

  16. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12(5): 1106-10.

  17. Bellentani S, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132(2): 112-7.

  18. Powell EE, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11(1): 74-80.

  19. Moran JR, et al. Steatohepatitis in obese children: a cause of chronic liver dysfunction. Am J Gastroenterol 1983; 78(6): 374-7.

  20. Baldridge AD, et al. Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J Pediatr 1995; 127(5): 700-4.

  21. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123(5): 1705-25.

  22. Bellentani S, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 1997; 41(6): 845-50.

  23. Becker U, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology 1996; 23(5): 1025-9.

  24. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999; 94(4): 1018-22.

  25. Yajima Y, et al. Ultrasonographical diagnosis of fatty liver: significance of the liver-kidney contrast. Tohoku J Exp Med 1983; 139(1): 43-50.

  26. Jacobs JE, et al. Diagnostic criteria for fatty infiltration of the liver on contrast-enhanced helical CT. AJR Am J Roentgenol 1998; 171(3): 659-64.

  27. Saadeh S, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123(3): 745-50.

  28. Siegelman ES, Rosen MA. Imaging of hepatic steatosis. Semin Liver Dis 2001; 21(1): 71-80.

  29. Longo,R, et al. Fatty infiltration of the liver. Quantification by 1H localized magnetic resonance spectroscopy and comparison with computed tomography. Invest Radiol 1993; 28(4): 297-302.

  30. Petersen KF, et al. Noninvasive assessment of hepatic triglyceride content in humans with 13C nuclear magnetic resonance spectroscopy. Hepatology 1996; 24(1): 114-7.

  31. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001; 21(1): 3-16.

  32. Younossi ZM, et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol 1998; 11(6): 560-5.

  33. Brunt EM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94(9): 2467-74.

  34. Teli MR, et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 22(6): 1714-9.

  35. Angulo P, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30(6): 1356-62.

  36. Matteoni CA, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116(6): 1413-9.

  37. Dixon JB, Bhathal PS, O’Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121(1): 91-100.

  38. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340(10): 745-50.

  39. Marrero JA, et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002; 36(6): 1349-54.

  40. Shimada M, et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2002; 37(1): 154-60.

  41. Bugianesi E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123(1): 134-40.

  42. Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2002; 17 Suppl: S186-90.

  43. Harrison SA, et al. Nonalcoholic steatohepatitis: what we know in the new millennium. Am J Gastroenterol 2002; 97(11): 2714-24.

  44. Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology 1998; 114(4): 842-5.

  45. Day CP. Non-alcoholic steatohepatitis (NASH): Where are we now and where are we going? Gut 2002; 50(5): 585-8.

  46. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001; 21(1): 27-41.

  47. Sanyal AJ, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120(5): 1183-92.

  48. Pessayre D, et al. Mitochondria in steatohepatitis. Semin Liver Dis 2001; 21(1): 57-69.

  49. Weltman MD, et al. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998; 27(1): 128-33.

  50. Andersen T, et al. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991; 12(2): 224-9.

  51. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990; 99(5): 1408-13.

  52. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 1998; 158(17): 1855-67.

  53. Klein S, Wadden T, Sugerman HJ. AGA technical review on obesity. Gastroenterology 2002; 123(3): 882-932.

  54. Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’. J Hepatol 2001; 35(1): 134-46.

  55. Laurin J, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996; 23(6): 1464-7.

  56. Angulo P, Lindor KD. Treatment of nonalcoholic fatty liver: present and emerging therapies. Semin Liver Dis 2001; 21(1): 81-8.

  57. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000; 136(6): 734-8.

  58. Lin HZ, et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000; 6(9): 998-1003.

  59. Marchesini G, et al. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358(9285): 893-4.

  60. Abdelmalek MF, et al. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001; 96(9): 2711-7.

  61. Miglio F, et al. Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study. Arzneimittelforschung 2000; 50(8): 722-7.

  62. Okan Gulbahar, ZAK, Galip Ersoz, Ulus S Akarea, Ahmet Musoglu. Treatment of Non-alcoholic Steatohepatitis with N-Acetylcystein. Gastroenterology 2000; 118: A1444 (Abstract).

  63. (http://www.OPTN.org). 2003.

  64. Ong J, et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 2001; 7(9): 797-801.

  65. Contos MJ, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001; 7(4): 363-73.

  66. Kim WR, et al. Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation 1996; 62(12): 1802-5.




2020     |     www.medigraphic.com